Meadow Creek Investment Management’s Amicus Therapeutics FOLD Stock Holding History

Meadow Creek Investment Management’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$8K	Buy	+960	New	+$10.4K	﹤0.01%	1356

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Meadow Creek Investment Management's FOLD Position: Q3 2019 in Review

Meadow Creek Investment Management opened a new position in Amicus Therapeutics (FOLD) in Q3 2019: 960 shares worth $8K. The stake represents ﹤0.01% of the portfolio and ranks #1356 among its holdings.

205 funds tracked by Wall St. Rank hold FOLD as of Q3 2019.

Meadow Creek Investment Management held 960 shares of Amicus Therapeutics worth $8K as of Q3 2019.
Amicus Therapeutics was a new Meadow Creek Investment Management position in Q3 2019.
Amicus Therapeutics made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1356 holding.
205 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.